343 The additional unexpected observations from the GLP-1, GIP and GCGR tri-agonist studies 342,344 warrant further investigation, as these studies highlight the incomplete understanding of metabolic hormonal synergism, and that further elucidation of this will likely lead to more efficacious treatments for diseases such as T2D
Modulates serotonin and dopamine systems in CNS and peripheral neural tissue
Brain Behav Immun 59:2137
For a proof-of-concept related to efficacy, future studies would need to include primary endpoints that directly measure changes in body weight, body composition, or relevant metabolic markers such as blood glucose, insulin levels, or HbA1c for T2DM patients
We also do not allow sourcing or listing products on our website from any 3rd party suppliers